Side by side: size, value over time, results, valuation, margins, growth, debt and shareholder returns, and any of thirty figures charted over the years (up to 6).
Open these as a peer group: up to 12 companies with suggested peers, each company's rank in the group and percentile in its sector and country, saved for you or your team.
From Jan 2020: how each company's value moved, whatever its size.
US$ billions, as reported in each year's annual results.
Revenue of the fiscal year. US dollars at each year's exchange rate.
| Measure | Amgen Inc.✕ AMGN · #73 in the world | AstraZeneca PLC✕ AZN · #76 in the world |
|---|---|---|
| Profile | ||
| Country | 🇺🇸 USA | 🇬🇧 UK |
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceutical | Pharmaceutical |
| Founded | 1980 | 1999 |
| Size | ||
| Market cap | $249.2 B | |
The largest companies, each against its nearest peers in value from the same industry.
| Fiscal year | Amgen Inc. | AstraZeneca PLC |
|---|---|---|
| 2025 | $36.8 BSEC | $58.7 BSEC |
| 2024 | $33.4 BSEC | $54.1 BSEC |
| 2023 | $28.2 BSEC | $45.8 BSEC |
| 2022 | $26.3 BSEC | $44.4 BSEC |
| 2021 | $26.0 BSEC | $37.4 BSEC |
| 2020 | $25.4 BSEC | $26.6 BSEC |
| 2019 | $23.4 BSEC | $24.4 BSEC |
| 2018 | $23.7 BSEC | $22.1 BSEC |
| 2017 | $22.8 BSEC | $22.5 BSEC |
| 2016 | $23.0 BSEC | $23.0 BSEC |
| 2015 | $21.7 BSEC | $24.7 BSEC |
| 2014 | $20.1 BSEC | — |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports; Ed. = the company's report (editors); WD = Wikidata, citing the annual report; Cap = value.today market caps. Hover a figure for its period.
| $242.6 B |
| Revenue | $36.8 B | $58.7 B |
|---|
| Net income | $7.7 B | $10.2 B▲ best |
|---|
| Employees | 25,200 | 89,900 |
|---|
| Valuation | ||
|---|---|---|
| P/E ratio | 26.5× | 23.7× |
| Price to sales | 6.4× | 4.1× |
| Price to book | 28.8× | 5.0× |
| Free cash flow yield | 3.3% | 4.8%▲ best |
| Profitability | ||
|---|---|---|
| Gross margin | 67.3% | 81.9%▲ best |
| Operating margin | 24.7%▲ best | 23.4% |
| Net margin | 21.0%▲ best | 17.4% |
| Return on equity | 106.1%▲ best | 22.9% |
| Return on invested capital | 14.4% | 17.5%▲ best |
| Growth | ||
|---|---|---|
| Revenue growth | 9.9%▲ best | 8.6% |
| Revenue growth, 3 years a year | 11.8%▲ best | 9.8% |
| Earnings per share growth | 88.2%▲ best | 45.3% |
| Financial strength | ||
|---|---|---|
| Debt to equity | 6.3× | 0.5×▲ best |
| Net debt to EBITDA | 3.2× | — |
| Interest cover | 3.3× | 8.1×▲ best |
| Cash | ||
|---|---|---|
| Free cash flow margin | 22.0%▲ best | 20.0% |
| Shareholder returns | ||
|---|---|---|
| Dividend yield | 2.1%▲ best | 2.0% |
| Shareholder yield | 2.1% | 2.3%▲ best |
| Strength scores | ||
|---|---|---|
| Piotroski F-score | 7 of 9 | 8 of 9▲ best |
| Altman Z-score zone | grey | safe |
|---|
| Data as of | Market cap Oct 2026; ratios FY2025 | Market cap Aug 2026; ratios FY2025 |
|---|
Market caps from exchange data or SEC filings on the date shown (* last known value, no current one); revenue and net income from the latest annual results; ratios worked out from each company's own statements for the fiscal year shown. ▲ marks the best of these companies where higher or lower is better; size and valuation multiples are marked for no one. Definitions: methodology.